W
WAVEMAN · COMPANY
VERU · Veru Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

VERU

VERU INC.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000863894
C-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$4.8K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
25
13F, latest reported quarter
REVENUE GROWTH
+3.6%
XBRL, annual
NET MARGIN
-134.6%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$4.8K over 180 days
+$4.8K over 90 days
more than 66% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
25 funds added or opened last quarter
below 67% of Pharma & Biotech
REVENUE
+3.6% year over year
more than 51% of Pharma & Biotech
MARGIN
-134.6% net margin
below 68% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
25 funds added or opened positions in the latest 13F quarter, of 62 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -16.2%
-16.2%12M
-36%-13%+11%+35%2025-092025-102025-122026-032026-052026-072026-09 2026-08-13 · BARNETTE K GARY bought $4.8K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $4.8K bought by insiders over 180 days, 25 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, VERU INC. insiders bought a net $4.8K of stock across 14 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
BARNETTE K GARY
Chief Scientific Officer
BUY
2026-08-13
1,800.0
$4.8K
Rankowitz Michael L
Director
BUY
2025-02-19
54,721.0
$31.7K
Rankowitz Michael L
Director
BUY
2025-02-18
95,279.0
$52.4K
FISCH HARRY
Chief Corporate Officer
BUY
2024-05-24
4,000.0
$5.0K
BARNETTE K GARY
Chief Scientific Officer
BUY
2024-05-24
5,000.0
$6.7K
14 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 9 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
VANGUARD CAPITAL MANAGEMENT LLC
698,439.0 sh
$2.2M
Alyeska Investment Group, L.P.
238,556.0 sh
$746.7K
OPPENHEIMER & CO INC
210,843.0 sh
$659.9K
BlackRock, Inc.
167,084.0 sh
$523.0K
RENAISSANCE TECHNOLOGIES LLC
164,450.0 sh
$514.7K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Fidelity Extended Market Index Fund
$201.5K POSITION · AS OF 2026-02-28
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$350.8K POSITION · AS OF 2026-03-31
0.0%
Fidelity Nasdaq Composite Index Fund
$22.0K POSITION · AS OF 2026-02-28
0.0%
Fidelity Series Total Market Index Fund
$48.1K POSITION · AS OF 2026-02-28
0.0%
Fidelity Total Market Index Fund
$59.4K POSITION · AS OF 2026-02-28
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$841.2K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 9 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
3
Phase 2
1 ACTIVE
4
Phase 3
0 ACTIVE
2
Multi-phase
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-092024-092023-092022-09
REVENUE—$16.9M$16.3M$39.4M
GROSS PROFIT—$5.9M$7.6M$30.6M
OPERATING INCOME$-24.8M$-36.2M$-93.8M$-83.5M
NET INCOME$-22.7M$-37.8M$-93.2M$-84.0M
EPS (DILUTED)——-1.10-1.05
OPERATING CASH FLOW$-30.0M$-21.7M$-88.0M$-47.5M
CASH$15.8M$24.9M$9.6M—
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →